The US Food and Drug Administration (FDA) today approved intradermal administration of the Jynneos vaccine for the treatment of monkeypox. The process, approved specifically for high-risk patients, was passed under the administration’s Emergency Use Authorization process. It follows the FDA’s decision on August 4 to declare monkeypox a public health emergency. Intradermal administration will allow providers to get five doses out of a one-dose vial.
Medscape Medical News will update this article as more information becomes available.
Source: Read Full Article